Back
Early Stage Triple Negative Breast Cancer Has Significantly Better Outcomes than More Advanced Disease: A Single Centre Retrospective Review
Caroline Hamm, Swati Kulkarni, Rasna Gupta, Amin Kay, John Mathews, Khalid Hirmiz, Indryas Woldie, Akmal Ghafoor, Tarek Elfiki, Sindu Kanjeekal, Ming Pan, Kenneth Schneider, Junaid Yousuf, Mohammad Jarrar, Colvin Springer, Maher El-Masri
J. Cancer Ther. Vol.7 No.10, September 22, 2016  DOI: 10.4236/jct.2016.710069
       (PDF  860K)     HTML      XML
A Rare Case of Adenoid Cystic Carcinoma of the Breast: Discussion and Review of the Literature
Saad Lannaz, Imane Ouziane, Youssef Bensouda, Hind Mrabti, Hassan Errihani
Case Rep. Clin. Med. Vol.3 No.7, July 23, 2014  DOI: 10.4236/crcm.2014.37096
       (PDF  1260K)     HTML      XML
Triple Negative Breast Cancer Treatment: Use of Platinum and Platinum Analogs
Manuela Fantini, Carlotta Santelmo, Fabrizio Drudi, Claudio Ridolfi, Eleonora Barzotti, Lorenzo Gianni, Valentina Arcangeli, Alessandra Affatato, Alberto Ravaioli
J. Cancer Ther. Vol.3 No.5, November 01, 2012  DOI: 10.4236/jct.2012.325097
       (PDF  73K)     HTML     
p53 Expression in Triple Negative Breast Carcinomas: Evidence of Age-Related and Racial Differences
Simone Davion, Megan Sullivan, Stephen Rohan, Kalliopi P. Siziopikou
J. Cancer Ther. Vol.3 No.5, October 31, 2012  DOI: 10.4236/jct.2012.325084
       (PDF  1077K)     HTML     
Biological Modulation of Parp Inhibition in Triple Negative Breast Cancer, a Combinational Approach Implementing Multitargeted Epigenetic Therapy (Mtet) with Parp Inhibition, in Advanced Breast Cancer: A Case Study
M. Nezami, Steve Hager, Julie Taguchi
J. Cancer Ther. Vol.9 No.9, September 11, 2018  DOI: 10.4236/jct.2018.99060
       (PDF  2152K)     HTML      XML
 
 
Top